List of Excipients in API regorafenib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing regorafenib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc | STIVARGA | regorafenib | 50419-171 | CELLULOSE, MICROCRYSTALLINE | 2031-04-08 |
| Bayer HealthCare Pharmaceuticals Inc | STIVARGA | regorafenib | 50419-171 | CROSCARMELLOSE SODIUM | 2031-04-08 |
| Bayer HealthCare Pharmaceuticals Inc | STIVARGA | regorafenib | 50419-171 | FERRIC OXIDE RED | 2031-04-08 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for regorafenib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
regorafenib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc | regorafenib | 50419-171 |
| >Company | >Ingredient | >NDC |
regorafenib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
regorafenib drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc | regorafenib | 50419-171 |
| >Company | >Ingredient | >NDC |
regorafenib drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
regorafenib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc | regorafenib | 50419-171 |
| >Company | >Ingredient | >NDC |
regorafenib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
regorafenib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc | regorafenib | 50419-171 |
| >Company | >Ingredient | >NDC |
regorafenib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LECITHIN, SOYBEAN
regorafenib drug variants containing LECITHIN, SOYBEAN
| Company | Ingredient | NDC |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc | regorafenib | 50419-171 |
| >Company | >Ingredient | >NDC |
regorafenib drug variants not containing LECITHIN, SOYBEAN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
regorafenib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc | regorafenib | 50419-171 |
| >Company | >Ingredient | >NDC |
regorafenib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 3350
regorafenib drug variants containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc | regorafenib | 50419-171 |
| >Company | >Ingredient | >NDC |
regorafenib drug variants not containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
regorafenib drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc | regorafenib | 50419-171 |
| >Company | >Ingredient | >NDC |
regorafenib drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE
regorafenib drug variants containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc | regorafenib | 50419-171 |
| >Company | >Ingredient | >NDC |
regorafenib drug variants not containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
regorafenib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc | regorafenib | 50419-171 |
| >Company | >Ingredient | >NDC |
regorafenib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
regorafenib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc | regorafenib | 50419-171 |
| >Company | >Ingredient | >NDC |
regorafenib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
regorafenib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc | regorafenib | 50419-171 |
| >Company | >Ingredient | >NDC |
regorafenib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
